首頁
KalVista Pharmaceuticals, Inc.

7月 2026KalVista Pharmaceuticals...的市場佔有率分析

KalVista is advancing science to empower everyday lives with innovative oral medicines. KalVista’s mission begins with hereditary angioedema, HAE.

健康 > 生物技術和製藥

域名kalvista.com

成立年份2004

僱員51 - 200

年度營收$15M - $25M

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.（包含公司地區）

kalvista.com

查看更多網站流量與參與度資訊

KalVista Pharmaceuticals, Inc.截至 7月 2026 的總收入為 15M - 25M

KalVista Pharmaceuticals, Inc. 熱門網域產生的總收入

KalVista Pharmaceuticals, Inc. 熱門網域 3 年內的總收入

KalVista Pharmaceuticals, Inc. 熱門網域的總收入

kalvista.com15M - 25M

透過銷售情報查看更多內容

KalVista Pharmaceuticals, Inc.的熱門網域總造訪量

了解KalVista Pharmaceuticals, Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

kalvista.com9.6K

透過銷售情報查看更多內容

KalVista Pharmaceuticals, Inc.的熱門網域平均造訪時長

分析KalVista Pharmaceuticals, Inc.參與度指標。

過去 3 個月平均造訪時長

子公司細目

kalvista.com00:00:25

透過銷售情報查看更多內容

KalVista Pharmaceuticals, Inc.的熱門網域平均頁面瀏覽量

了解KalVista Pharmaceuticals, Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

kalvista.com1.93

透過銷售情報查看更多內容

KalVista Pharmaceuticals, Inc.按網域劃分的熱門競爭對手

7月 2026的熱門類似網站，依相似度排名

akebia.com公司名Akebia Therapeutics僱員201 - 500總部美國, 馬薩諸塞州, Cambridge年度營收$200M - $500M訪問總量11.1K健康 > 生物技術和製藥

使用的熱門技術KalVista Pharmaceuticals, Inc.

这些是KalVista Pharmaceuticals, Inc.顶级域名使用的行业网站技术

小工具 (5)

Twemoji

付費廣告 (4)

Facebook Custom Audiences

內容管理系統 (3)

WordPress

轉換與分析 (3)

Google Analytics

更多技術

11

檢視所有

新聞與訊號來自KalVista Pharmaceuticals, Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Nicole Sweeny leaves KalVista Pharmaceuticals, Inc. as Chief Commercial Officer.Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, was elected to the Board of Directors at the Company's Annual Meeting of Stockholders on June 22, 2026.

新聞KalVista Pharmaceuticals, Inc. is developing portfolio of novel, small molecule protease inhibitors for diseases like hereditary angioedema on Jun 12th '26.* For KalVista (the acquirer): As a private, clinical-stage company, KalVista was developing a portfolio of novel, small molecule protease inhibitors for diseases like hereditary angioedema (HAE).

新聞Chiesi Group was planning to acquire KalVista Pharmaceuticals, Inc. for $1.9B on Aug 1st '25.Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech's oral therapy Ekterly to treat severe swelling episodes caused by the rare genetic disorder hereditary angioedema.